Putative β-Barrel Outer Membrane Proteins of the Bovine Digital Dermatitis-Associated Treponemes: Identification, Functional Characterization, and Immunogenicity
Overview
Affiliations
Bovine digital dermatitis (BDD), an infectious disease of the bovine foot with a predominant treponemal etiology, is a leading cause of lameness in dairy and beef herds worldwide. BDD is poorly responsive to antimicrobial therapy and exhibits a relapsing clinical course; an effective vaccine is therefore urgently sought. Using a reverse vaccinology approach, the present study surveyed the genomes of the three BDD-associated phylogroups for putative β-barrel outer membrane proteins and considered their potential as vaccine candidates. Selection criteria included the presence of a signal peptidase I cleavage site, a predicted β-barrel fold, and cross-phylogroup homology. Four candidate genes were overexpressed in BL21(DE3), refolded, and purified. Consistent with their classification as β-barrel OMPs, circular-dichroism spectroscopy revealed the adoption of a predominantly β-sheet secondary structure. These recombinant proteins, when screened for their ability to adhere to immobilized extracellular matrix (ECM) components, exhibited a diverse range of ligand specificities. All four proteins specifically and dose dependently adhered to bovine fibrinogen. One recombinant protein was identified as a candidate diagnostic antigen (disease specificity, 75%). Finally, when adjuvanted with aluminum hydroxide and administered to BDD-naive calves using a prime-boost vaccination protocol, these proteins were immunogenic, eliciting specific IgG antibodies. In summary, we present the description of four putative treponemal β-barrel OMPs that exhibit the characteristics of multispecific adhesins. The observed interactions with fibrinogen may be critical to host colonization and it is hypothesized that vaccination-induced antibody blockade of these interactions will impede treponemal virulence and thus be of therapeutic value.
Kamaruzaman I, Staton G, Ainsworth S, Carter S, Evans N Microorganisms. 2024; 12(2).
PMID: 38399649 PMC: 10891613. DOI: 10.3390/microorganisms12020245.
Jimenez-Vasquez V, Calvay-Sanchez K, Zarate-Sulca Y, Mendoza-Mujica G PLoS Negl Trop Dis. 2023; 17(5):e0011321.
PMID: 37228134 PMC: 10246785. DOI: 10.1371/journal.pntd.0011321.
Singh C, Mintie C, Ndiaye M, Chhabra G, Roy S, Sullivan R Front Immunol. 2023; 13:1051472.
PMID: 36741360 PMC: 9893861. DOI: 10.3389/fimmu.2022.1051472.
Staton G, Clegg S, Ainsworth S, Armstrong S, Carter S, Radford A PLoS Pathog. 2021; 17(3):e1009464.
PMID: 33780514 PMC: 8049484. DOI: 10.1371/journal.ppat.1009464.
TLR4 Agonist Combined with Trivalent Protein JointS of Provides Immunological Protection in Animals.
Wang Z, Guo M, Kong L, Gao Y, Ma J, Cheng Y Vaccines (Basel). 2021; 9(2).
PMID: 33671673 PMC: 7926372. DOI: 10.3390/vaccines9020184.